Erasca, Inc. (ERAS) Dividend History

Company News

• Erasca to Present at Upcoming Investor Conferences in June

  Erasca, a clinical-stage precision oncology company, announced the advancement of its RAS-targeting franchise, with IND clearance for ERAS-0015 and IND submission for ERAS-4001, both ahead of schedule. The company expects to report Phase 1 monotherapy data for both programs in 2026 and has a projected cash runway of more than 3 years.

  GlobeNewswire Inc.
• Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

  Erasca, Inc. (ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announced its participation in the Guggenheim Securities SMID Cap Biotech Conference, where management will present and hold one-on-one investor meetings.

  GlobeNewswire Inc.
• Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

  The oncology field is advancing with emerging immunotherapies and AI-driven personalized cell therapies. Key players like Oncolytics Biotech, Erasca, Allogene Therapeutics, Context Therapeutics, and Recursion Pharmaceuticals are driving progress in areas like breast, GI, and renal cell cancers.

  Benzinga

  Featured Companies: ALLO CNTX ONCY RXRX
• Erasca to Present at Upcoming Investor Conferences

  Erasca, a clinical-stage precision oncology company, announced its participation in upcoming investor conferences, including the Guggenheim Securities Healthcare Innovation Conference, Jefferies London Healthcare Conference, and the 7th Annual Evercore HealthCONx Conference.

  GlobeNewswire Inc.
• Should You Buy Erasca, Inc. (ERAS) After Golden Cross?

  Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

  Zacks Investment Research